LGC (London, UK) has announced its acquisition of Maine Standards Company (Cumberland Foreside, Maine, USA).
LGC (London, UK) has announced its acquisition of Maine Standards Company (Cumberland Foreside, Maine, USA). A leading provider of calibration verification materials in the US, Maine Standards Company bolsters LGC’s portfolio of reference materials and proficiency testing schemes available for the clinical market.
Euan O’Sullivan, Managing Director of LGC’s Standards Divison, expressed his delight in welcoming the Maine based company to LGC, and commented “Our two organizations represent a highly complementary commercial and cultural fit, with a common commitment to developing products of the very highest quality for the benefit of our customers. We look forward to working with Maine Standards Company to complete its leading portfolio of calibration verification materials for the US market, whilst using our global network to expand sales of these products internationally.”
Maine Standards Company will continue to operate from its recently opened facility near Portland, Maine. Tom Happe, Founder and President of Maine Standards Company, hoped the union of the two companies capabilities would ease the transition of Maine Standards Company into the global market and address growing interest in their services from overseas.
Both companies hope the combination of their respective analytical capabilities will lead to the development of new products for their mutual customers.
For more information please visit www.lgcgroup.com
New TRC Facility Accelerates Innovation and Delivery
April 25th 2025We’ve expanded our capabilities with a state-of-the-art, 200,000 sq ft TRC facility in Toronto, completed in 2024 and staffed by over 100 PhD- and MSc-level scientists. This investment enables the development of more innovative compounds, a broader catalogue and custom offering, and streamlined operations for faster delivery. • Our extensive range of over 100,000 high-quality research chemicals—including APIs, metabolites, and impurities in both native and stable isotope-labelled forms—provides essential tools for uncovering molecular disease mechanisms and exploring new opportunities for therapeutic intervention.
New Guide: Characterising Impurity Standards – What Defines “Good Enough?”
April 25th 2025Impurity reference standards (IRSs) are essential for accurately identifying and quantifying impurities in pharmaceutical development and manufacturing. Yet, with limited regulatory guidance on how much characterisation is truly required for different applications, selecting the right standard can be challenging. To help, LGC has developed a new interactive multimedia guide, packed with expert insights to support your decision-making and give you greater confidence when choosing the right IRS for your specific needs.